应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
02196 复星医药
休市中 04-19 16:08:35
11.440
-0.060
-0.52%
最高
11.540
最低
11.320
成交量
342.30万
今开
11.500
昨收
11.500
日振幅
1.91%
总市值
305.72亿
流通市值
63.14亿
总股本
26.72亿
成交额
3,911万
换手率
0.62%
流通股本
5.52亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
将“颜值”转化为“产值” 豫园股份与菏泽共建“中国牡丹”产业研究室
中国财富网 · 04-19 19:50
将“颜值”转化为“产值” 豫园股份与菏泽共建“中国牡丹”产业研究室
复星减持Ageas股份 进退有序 聚焦深挖矿
金融界 · 04-19 14:14
复星减持Ageas股份 进退有序 聚焦深挖矿
家庭医生概念盘中跳水,复星医药跌0.79%
自选股智能写手 · 04-19 10:25
家庭医生概念盘中跳水,复星医药跌0.79%
干细胞概念盘中拉升,开能健康涨3.26%
自选股智能写手 · 04-18 09:51
干细胞概念盘中拉升,开能健康涨3.26%
北向资金4月17日净买入复星医药24.57万股 连续3日增持
自选股智能写手 · 04-18 09:30
北向资金4月17日净买入复星医药24.57万股 连续3日增持
复星医药(02196.HK)子公司药物获批开展临床试验
阿斯达克财经 · 04-17 17:49
复星医药(02196.HK)子公司药物获批开展临床试验
复星医药(02196.HK)控股子公司药物注册申请获国家药监局受理
阿斯达克财经 · 04-17 17:49
复星医药(02196.HK)控股子公司药物注册申请获国家药监局受理
复星医药(02196):膦甲酸钠注射液药品注册申请获国家药监局受理
智通财经 · 04-17 17:47
复星医药(02196):膦甲酸钠注射液药品注册申请获国家药监局受理
复星医药:控股子公司获膦甲酸钠注射液药品注册申请受理
国际金融报 · 04-17 17:13
复星医药:控股子公司获膦甲酸钠注射液药品注册申请受理
复星医药(02196.HK)4月29日举行董事会会议考虑及通过一季度业绩
格隆汇资讯 · 04-17 16:50
复星医药(02196.HK)4月29日举行董事会会议考虑及通过一季度业绩
复星医药(600196.SH):膦甲酸钠注射液注册申请获受理
智通财经网 · 04-17 16:47
复星医药(600196.SH):膦甲酸钠注射液注册申请获受理
复星医药:子公司膦甲酸钠注射液药品注册申请获受理
证券时报 · 04-17 16:42
复星医药:子公司膦甲酸钠注射液药品注册申请获受理
复星医药(600196.SH):控股子公司复宏汉霖(02696)获药品临床试验批准
智通财经 · 04-17 16:40
复星医药(600196.SH):控股子公司复宏汉霖(02696)获药品临床试验批准
复星医药:控股子公司获药品临床试验批准
金融界 · 04-17 16:38
复星医药:控股子公司获药品临床试验批准
智通AH统计|4月17日
智通财经 · 04-17 16:15
智通AH统计|4月17日
南向资金4月16日净买入复星医药149.70万股 连续5日增持
自选股智能写手 · 04-17
南向资金4月16日净买入复星医药149.70万股 连续5日增持
CAR-T疗法填补临床空白,复星凯特中国首款淋巴瘤按疗效价值支付计划关爱患者
新民晚报 · 04-16
CAR-T疗法填补临床空白,复星凯特中国首款淋巴瘤按疗效价值支付计划关爱患者
民营医院概念盘中跳水,复星医药跌1.50%
自选股智能写手 · 04-16
民营医院概念盘中跳水,复星医药跌1.50%
新冠药物概念盘中跳水,复星医药跌0.88%
自选股智能写手 · 04-16
新冠药物概念盘中跳水,复星医药跌0.88%
细胞免疫治疗概念盘中跳水,复星医药跌0.13%
自选股智能写手 · 04-16
细胞免疫治疗概念盘中跳水,复星医药跌0.13%
暂无数据
公司概况
公司名称:
复星医药
所属市场:
SEHK
上市日期:
--
主营业务:
上海复星医药(集团)股份有限公司是一家主要从事医药产品研发、制造与销售的中国公司。该公司的医药产品主要用于新陈代谢及消化系统、心血管系统、中枢神经系统、血液系统、抗肿瘤及抗感染等疾病治疗领域。该公司还从事医疗器械与医学诊断业务以及医疗服务。其产品主要销往中国国内及海外市场。
发行价格:
--
{"stockData":{"symbol":"02196","market":"HK","secType":"STK","nameCN":"复星医药","latestPrice":11.44,"timestamp":1713514115032,"preClose":11.5,"halted":0,"volume":3422970,"delay":0,"floatShares":551940500,"shares":2672398711,"eps":0.96527636,"marketStatus":"休市中","marketStatusCode":7,"change":-0.06,"latestTime":"04-19 16:08:35","open":11.5,"high":11.54,"low":11.32,"amount":39106470,"amplitude":0.01913,"askPrice":11.46,"askSize":2500,"bidPrice":11.44,"bidSize":58500,"shortable":3,"etf":0,"ttmEps":0.9611208560263136,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1713749400000},"adr":0,"adjPreClose":11.5,"dividendRate":0.025491,"openAndCloseTimeList":[[1713490200000,1713499200000],[1713502800000,1713513600000]],"volumeRatio":0.8050635483361617,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600196","market":"SH","secType":"STK","nameCN":"复星医药","latestPrice":22.51,"timestamp":1713510000000,"preClose":22.77,"halted":0,"volume":5892389,"delay":0,"premium":"-52.94"}},"requestUrl":"/m/hq/s/02196/tweets","defaultTab":"tweets","newsList":[{"id":"2428655653","title":"将“颜值”转化为“产值” 豫园股份与菏泽共建“中国牡丹”产业研究室","url":"https://stock-news.laohu8.com/highlight/detail?id=2428655653","media":"中国财富网","top":-1,"share":"https://www.laohu8.com/m/news/2428655653?lang=zh_cn&edition=full","pubTime":"2024-04-19 19:50","pubTimestamp":1713527453,"startTime":"0","endTime":"0","summary":"4月17日,豫园股份旗下复星津美化妆品与山东省菏泽市牡丹发展服务中心正式签订战略合作协议,启动共建“中国牡丹”产业研究实验室,助力菏泽产业提升自主科创研发能力,以新质生产力开辟国内化妆品产业与花卉产业高质量发展新路径。此番“中国牡丹”产业研究实验室的创建进一步推动了“美丽经济”与“花样经济”的共鸣。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404191959278795a2c9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404191959278795a2c9&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428096688","title":"复星减持Ageas股份 进退有序 聚焦深挖矿","url":"https://stock-news.laohu8.com/highlight/detail?id=2428096688","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2428096688?lang=zh_cn&edition=full","pubTime":"2024-04-19 14:14","pubTimestamp":1713507277,"startTime":"0","endTime":"0","summary":"近期,复星在 保险 业务领域的一系列动作引发市场广泛关注。复星出售Ageas股份,将获得约6.26亿至6.70亿欧元的交易对价,并预计实现未经审计税前利润约6,000万至6,500万欧元,这不仅有助于其精简和优化投资组合,还能提升其财务表现与核心业务竞争力。复星聚焦主业“深挖矿”的战略成果,在其核心子公司核心业务上得到最为充分的体现。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404191419428b39790c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404191419428b39790c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428577419","title":"家庭医生概念盘中跳水,复星医药跌0.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2428577419","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428577419?lang=zh_cn&edition=full","pubTime":"2024-04-19 10:25","pubTimestamp":1713493551,"startTime":"0","endTime":"0","summary":"04月19日,家庭医生概念盘中跳水,截至10点25分,家庭医生概念整体指数下跌1.02%,报819.310点。从个股上来看,该概念的成分股中,复星医药跌0.79%,福瑞股份、中国平安、思创医惠跌幅居前。从资金上来看,截止发稿,家庭医生概念主力净流入为-3.63亿,其中中元股份受到资金热捧,主力净流入298.64万;拉长时间线来看,该板块近20日主力资金净流入-68.76亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041910255187e81fef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041910255187e81fef&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428835885","title":"干细胞概念盘中拉升,开能健康涨3.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2428835885","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428835885?lang=zh_cn&edition=full","pubTime":"2024-04-18 09:51","pubTimestamp":1713405088,"startTime":"0","endTime":"0","summary":"04月18日,干细胞概念盘中拉升,截至09点51分,干细胞概念整体指数上涨0.52%,报723.850点。从个股上来看,该概念的成分股中,开能健康涨3.26%,九 芝 堂、苏常柴A、复星医药涨幅居前。从资金上来看,截止发稿,干细胞概念主力净流入为-2727.32万,其中复星医药受到资金热捧,主力净流入493.72万;拉长时间线来看,该板块近20日主力资金净流入-15.02亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041809512887e8186c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041809512887e8186c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428558583","title":"北向资金4月17日净买入复星医药24.57万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2428558583","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428558583?lang=zh_cn&edition=full","pubTime":"2024-04-18 09:30","pubTimestamp":1713403808,"startTime":"0","endTime":"0","summary":"4月17日, 北向资金增持复星医药24.57万股,连续3日增持。截止当日收盘,沪股通共持有复星医药4799.05万股,占流通股2.26%。沪股通增持金额前五个股分别为国电电力、大秦铁路、同仁堂、中国平安、赤峰黄金。复星医药近5个交易日下跌1.21%,沪股通累计增持33.59万股;近20个交易日下跌9.24%,沪股通累计增持47.02万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404180930448b32443f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404180930448b32443f&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428397631","title":"复星医药(02196.HK)子公司药物获批开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2428397631","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2428397631?lang=zh_cn&edition=full","pubTime":"2024-04-17 17:49","pubTimestamp":1713347340,"startTime":"0","endTime":"0","summary":"复星医药(02196.HK) 公布,其子公司上海复宏汉霖生物技术股份有限公司(02696.HK) 近日收到国家药品监督管理局批准其自主研发的 HLX53(即抗 TIGIT 的Fc融合蛋白)联合汉斯状®(即斯鲁利单抗注射液)和汉贝泰®(即贝伐珠单抗注射液)一线治疗局部晚期或转移性肝细胞癌(HCC)开展临床试验。复宏汉霖拟于条件具备后,于内地开展相关治疗方案的II期临床试验。(vc/u)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-17 16:25。)AASTOCKS新闻","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20220221174705869_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20220221174705869_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1343032/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2428397269","title":"复星医药(02196.HK)控股子公司药物注册申请获国家药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2428397269","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2428397269?lang=zh_cn&edition=full","pubTime":"2024-04-17 17:49","pubTimestamp":1713347340,"startTime":"0","endTime":"0","summary":"复星医药(02196.HK) 公布,旗下控股子公司桂林南药股份有限公司的膦甲酸钠注射液药品注册申请,于近日获中国国家药品监督管理局受理。相关药物拟用于,获得性免疫缺陷综合症患者的巨细胞病毒性视网膜炎;以及免疫功能低下患者的耐阿昔洛韦单纯疱疹病毒性的皮肤黏膜感染。截至今年3月,集团现阶段针对该新药物的累计研发投入约417万元人民币。(js/a)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-17 16:25。)AASTOCKS新闻","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20170911103105061_s.JPG","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20170911103105061_s.JPG"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1343034/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2428397685","title":"复星医药(02196):膦甲酸钠注射液药品注册申请获国家药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2428397685","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2428397685?lang=zh_cn&edition=full","pubTime":"2024-04-17 17:47","pubTimestamp":1713347265,"startTime":"0","endTime":"0","summary":"智通财经APP讯,复星医药 发布公告,该公司控股子公司桂林南药股份有限公司的膦甲酸钠注射液的药品注册申请于近日获国家药品监督管理局受理。截至2024年3月,该集团现阶段针对该新药的累计研发投入约为人民币417万元。根据IQVIA CHPA最新数据,2022年,膦甲酸钠注射剂于中国境内的销售额约为人民币7672万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1103928.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2428391759","title":"复星医药:控股子公司获膦甲酸钠注射液药品注册申请受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2428391759","media":"国际金融报","top":-1,"share":"https://www.laohu8.com/m/news/2428391759?lang=zh_cn&edition=full","pubTime":"2024-04-17 17:13","pubTimestamp":1713345222,"startTime":"0","endTime":"0","summary":"复星医药公告,控股子公司获膦甲酸钠注射液药品注册申请受理。该新药系化学药品,拟用于(1)获得性免疫缺陷综合征(AIDS)患者的巨细胞病毒性(CMV)视网膜炎;(2)免疫功能低下患者的耐阿昔洛韦单纯疱疹病毒性(HSV)的皮肤黏膜感染。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404171713547a536957&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404171713547a536957&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428399956","title":"复星医药(02196.HK)4月29日举行董事会会议考虑及通过一季度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2428399956","media":"格隆汇资讯","top":-1,"share":"https://www.laohu8.com/m/news/2428399956?lang=zh_cn&edition=full","pubTime":"2024-04-17 16:50","pubTimestamp":1713343824,"startTime":"0","endTime":"0","summary":"格隆汇4月17日丨复星医药(02196.HK)公布,谨定于2024年4月29日(星期一)举行董事会会议,藉以(其中包括)考虑及通过公司及其附属公司截至2024年3月31日止三个月的第一季度业绩并予以刊发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041716503587881dab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041716503587881dab&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428964193","title":"复星医药(600196.SH):膦甲酸钠注射液注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2428964193","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2428964193?lang=zh_cn&edition=full","pubTime":"2024-04-17 16:47","pubTimestamp":1713343621,"startTime":"0","endTime":"0","summary":"智通财经APP讯,复星医药(600196.SH)公告,公司控股子公司桂林南药股份有限公司的膦甲酸钠注射液(以下简称“该新药”)的药品注册申请于近日获国家药品监督管理局受理。据悉,该新药系化学药品,拟用于(1)获得性免疫缺陷综合征(AIDS)患者的巨细胞病毒性(CMV)视网膜炎;(2)免疫功能低下患者的耐阿昔洛韦单纯疱疹病毒性(HSV)的皮肤黏膜感染。更多港股重磅资讯,下载智通财经app更多港股及海外理财资讯,请点击www.zhitongcaijing.com(搜索“智通财经”);欲加入智通港股投资群,请加智通客服微信(ztcjkf)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1103871.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2428399869","title":"复星医药:子公司膦甲酸钠注射液药品注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2428399869","media":"证券时报","top":-1,"share":"https://www.laohu8.com/m/news/2428399869?lang=zh_cn&edition=full","pubTime":"2024-04-17 16:42","pubTimestamp":1713343344,"startTime":"0","endTime":"0","summary":"证券时报e公司讯,复星医药(600196)4月17日晚间公告,控股子公司复宏汉霖近日收到国家药监局关于同意其自主研发的HLX53(即抗TIGIT的Fc融合蛋白)联合汉斯状®(即斯鲁利单抗注射液)和汉贝泰®(即贝伐珠单抗注射液)一线治疗局部晚期或转移性肝细胞癌(HCC)开展临床试验的批准。控股子公司桂林南药的膦甲酸钠注射液的药品注册申请近日获国家药监局受理。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240417164226878815b7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240417164226878815b7&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428965243","title":"复星医药(600196.SH):控股子公司复宏汉霖(02696)获药品临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2428965243","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2428965243?lang=zh_cn&edition=full","pubTime":"2024-04-17 16:40","pubTimestamp":1713343232,"startTime":"0","endTime":"0","summary":"智通财经APP讯,复星医药(600196.SH)公告,公司控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司(“复宏汉霖”)于近日收到国家药品监督管理局关于同意其自主研发的HLX53(即抗TIGIT的Fc融合蛋白)联合汉斯状®(即斯鲁利单抗注射液)和汉贝泰®(即贝伐珠单抗注射液)一线治疗局部晚期或转移性肝细胞癌(HCC)(“该治疗方案”)开展临床试验的批准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1103865.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2428984399","title":"复星医药:控股子公司获药品临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2428984399","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2428984399?lang=zh_cn&edition=full","pubTime":"2024-04-17 16:38","pubTimestamp":1713343121,"startTime":"0","endTime":"0","summary":"复星医药公告,公司控股子公司复宏汉霖于近日收到国家药监局关于同意其自主研发的HLX53(即抗TIGIT的Fc融合蛋白)联合汉斯状(即斯鲁利单抗注射液)和汉贝泰(即贝伐珠单抗注射液)一线治疗局部晚期或转移性肝细胞癌(HCC)开展临床试验的批准。复宏汉霖拟于条件具备后于中国境内(不包括港澳台地区,下同)开展该治疗方案的II期临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404171645398b2e117b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404171645398b2e117b&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428398075","title":"智通AH统计|4月17日","url":"https://stock-news.laohu8.com/highlight/detail?id=2428398075","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2428398075?lang=zh_cn&edition=full","pubTime":"2024-04-17 16:15","pubTimestamp":1713341706,"startTime":"0","endTime":"0","summary":"智通财经APP数据显示,截止4月17日收盘,东北电气、弘业期货、浙江世宝分列AH溢价率前三位,溢价率分别为1167.61%、751.59%、608.00%;紫金矿业、比亚迪股份、招商银行分列AH溢价率末三位,溢价率分别为24.77%、25.19%、25.64%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1103830.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2428332668","title":"南向资金4月16日净买入复星医药149.70万股 连续5日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2428332668","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428332668?lang=zh_cn&edition=full","pubTime":"2024-04-17 09:31","pubTimestamp":1713317479,"startTime":"0","endTime":"0","summary":"4月16日, 南向资金增持复星医药149.70万股,连续5日增持。截止当日收盘,港股通共持有复星医药24978.96万股,占流通股45.24%。复星医药近5个交易日下跌8.23%,港股通累计增持470.85万股;近20个交易日下跌23.93%,港股通累计增持1245.30万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041709493287869a1b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041709493287869a1b&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427439598","title":"CAR-T疗法填补临床空白,复星凯特中国首款淋巴瘤按疗效价值支付计划关爱患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2427439598","media":"新民晚报","top":-1,"share":"https://www.laohu8.com/m/news/2427439598?lang=zh_cn&edition=full","pubTime":"2024-04-16 17:10","pubTimestamp":1713258629,"startTime":"0","endTime":"0","summary":"CAR-T细胞疗法具有个体化治疗的优势,能够根据患者的具体情况定制治疗方案,提供更精准、更有效的癌症治疗策略。另外,科室为接受CAR-T治疗患者免费提供CAR扩增和基因测序等检测,可帮助减轻患者的经济负担。2024年1月,复星凯特宣布推出“奕凯达中国首款淋巴瘤按疗效价值支付计划”,推动CAR-T细胞治疗产品惠及更多患者。据了解,奕凯达中国首款淋巴瘤按疗效价值支付计划将严格参照《2014版Lugano评估标准》评估CR结果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041617151587838d14&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041617151587838d14&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427869476","title":"民营医院概念盘中跳水,复星医药跌1.50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2427869476","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2427869476?lang=zh_cn&edition=full","pubTime":"2024-04-16 10:32","pubTimestamp":1713234761,"startTime":"0","endTime":"0","summary":"04月16日,民营医院概念盘中跳水,截至10点32分,民营医院概念整体指数下跌5.05%,报1421.700点。从个股上来看,该概念的成分股中,复星医药跌1.50%,京东方A、华邦健康、物产中大跌幅居前。从资金上来看,截止发稿,民营医院概念主力净流入为-2.43亿,其中人福医药受到资金热捧,主力净流入1313.92万;拉长时间线来看,该板块近20日主力资金净流入-43.75亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404161032417a5302bd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404161032417a5302bd&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427865552","title":"新冠药物概念盘中跳水,复星医药跌0.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2427865552","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2427865552?lang=zh_cn&edition=full","pubTime":"2024-04-16 10:06","pubTimestamp":1713233168,"startTime":"0","endTime":"0","summary":"04月16日,新冠药物概念盘中跳水,截至10点06分,新冠药物概念整体指数下跌4.69%,报458.010点。从个股上来看,该概念的成分股中,复星医药跌0.88%,东北制药、以岭药业、华邦健康跌幅居前。从资金上来看,截止发稿,新冠药物概念主力净流入为-1.62亿,其中中国医药受到资金热捧,主力净流入1850.82万;拉长时间线来看,该板块近20日主力资金净流入-43.94亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240416100608861e60f9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240416100608861e60f9&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427850778","title":"细胞免疫治疗概念盘中跳水,复星医药跌0.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2427850778","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2427850778?lang=zh_cn&edition=full","pubTime":"2024-04-16 09:38","pubTimestamp":1713231523,"startTime":"0","endTime":"0","summary":"04月16日,细胞免疫治疗概念盘中跳水,截至09点38分,细胞免疫治疗概念整体指数下跌2.06%,报715.330点。从个股上来看,该概念的成分股中,复星医药跌0.13%,跌幅居前。从资金上来看,截止发稿,细胞免疫治疗概念主力净流入为-6445.87万,其中博晖创新受到资金热捧,主力净流入411.90万;拉长时间线来看,该板块近20日主力资金净流入-129.91亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041609384387e80956&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041609384387e80956&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fosunpharma.com","stockEarnings":[{"period":"1week","weight":-0.0338},{"period":"1month","weight":-0.177},{"period":"3month","weight":-0.2175},{"period":"6month","weight":-0.3349},{"period":"1year","weight":-0.5012},{"period":"ytd","weight":-0.3271}],"compareEarnings":[{"period":"1week","weight":-0.0298},{"period":"1month","weight":-0.0193},{"period":"3month","weight":0.0598},{"period":"6month","weight":-0.0552},{"period":"1year","weight":-0.2046},{"period":"ytd","weight":-0.0483}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海复星医药(集团)股份有限公司是一家主要从事医药产品研发、制造与销售的中国公司。该公司的医药产品主要用于新陈代谢及消化系统、心血管系统、中枢神经系统、血液系统、抗肿瘤及抗感染等疾病治疗领域。该公司还从事医疗器械与医学诊断业务以及医疗服务。其产品主要销往中国国内及海外市场。","yearOnYearQuotes":[{"month":1,"riseRate":0.416667,"avgChangeRate":-0.049465},{"month":2,"riseRate":0.75,"avgChangeRate":0.030196},{"month":3,"riseRate":0.666667,"avgChangeRate":0.05388},{"month":4,"riseRate":0.416667,"avgChangeRate":0.033058},{"month":5,"riseRate":0.454545,"avgChangeRate":0.026266},{"month":6,"riseRate":0.363636,"avgChangeRate":-0.041074},{"month":7,"riseRate":0.545455,"avgChangeRate":0.017881},{"month":8,"riseRate":0.272727,"avgChangeRate":-0.057829},{"month":9,"riseRate":0.363636,"avgChangeRate":-0.025941},{"month":10,"riseRate":0.545455,"avgChangeRate":0.035528},{"month":11,"riseRate":0.5,"avgChangeRate":0.052861},{"month":12,"riseRate":0.5,"avgChangeRate":0.024492}],"exchange":"SEHK","name":"复星医药","nameEN":"FOSUN PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复星医药(02196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复星医药,02196,复星医药股票,复星医药股票老虎,复星医药股票老虎国际,复星医药行情,复星医药股票行情,复星医药股价,复星医药股市,复星医药股票价格,复星医药股票交易,复星医药股票购买,复星医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复星医药(02196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}